Healthcare >> CEO Interviews >> November 15, 2010
Dave Martin has been a driver in building shareholder value over the last 10 years in three companies. He was appointed the Cardiovascular Systems' CEO in February 2007 and has served on the board since Aug. 15, 2006. Prior to that, Mr. Martin was COO for FoxHollow Technologies (IPO 2004), where he directed their commercial plan. Prior to FoxHollow, he was VP of Global Sales for Rita Medical Systems, (IPO 2000), and before that, he was Director of U.S. Sales for CardioThoracic Systems, (IPO 1996). Mr. Martin has also held sales and sales management positions for Procter & Gamble, Boston Scientific and Guidant Corporation. Profile
TWST: Let's start with a brief history and overview of Cardiovascular Systems Inc.
Mr. Martin: In September 2007 the FDA cleared the Cardiovascular Systems (CSII) Diamondback360 device for the
